Conversations on Today’s Priorities!
Monday, 15 March
DIAmond 1 - Health Emergency Preparedness
The DIAmond session will illustrate the European Network’s Health Emergency Preparedness, experience so far under various health crises including COVID-19, lessons learned and how to improve the system. Hear from the European Medicines Agency, the European Commission, national competent authorities, ECDC and WHO.
DIAmond 2 - Updates from WHO
DIAmond 3 - What does Good Look Like? Shaping the Environment to Manage Antimicrobial Resistance and Promote Sustainable Development of Anti-infectives and Vaccines
Antimicrobial resistance is a major public health concern with increasing urgency; no stakeholder or policymaker alone can solve it. To take stock of the various initiatives and discuss collaborative efforts, the session gathers leaders from different stakeholder groups to identify the synergies between the EMA RSS, European Regulators’ Network Strategy, Pharmaceutical Strategy and ICMRA to create a sustainable environment for antimicrobials, anti-infectives and vaccines.
DIAmond 4 - Big Data Force
The report of the HMA-EMA joint Big Data Task Force was published on 20 January 2020 and made 10 big bold recommendations. So what happens next? Here the recommendations are reviewed and key stakeholders share their views on how we move from recommendations to action for ‘evolving data-driven regulation’.
Tuesday, 16 March
DIAmond 5 - European Medicines Agencies Regulatory Network Strategy to 2025
This DIAmond session will illustrate the European Medicines Agencies Network Strategy 2025 and debate how this strategy aims at addressing challenges and creating opportunities for health care systems. Hear from the EMA and HMA on the creation, consultation and planned implementation of the European Medicines Agencies Network Strategy 2025 and gain insights on the perspective of stakeholders including patient representatives, healthcare professionals and industry.
DIAmond 6 - Key Lessons Learned from COVID-19 for the Future of Pharmaceutical Policy
The COVID-19 outbreak in Europe has catalysed some long-standing issues in the functioning of pharmaceutical policy as well as medicines supply . The policy areas which need a further revision will be discussed during the session.
EU Regulatory Town Hall: Is the European Framework Agile Enough?
The European Regulatory Town Hall will debate challenges and opportunities the European regulatory landscape is facing under COVID-19. Is the framework agile enough? How is the system addressing rapid advances in science and technology in the context of COVID-19 and how is it adapting to further enable research and development in Europe. Hear from the European Commission, the European Medicines Agency, patient representatives, EFPIA and an SME, academia, health care professionals and national competent authorities.
Wednesday, 17 March
DIAmond 7 - Various Facets of Patient Voice, Role and Involvement in Medicines Lifecyles Pathways
DIAmond 8 - Medicines Shortages Changing the Paradigm from Mitigation to Prevention
Shortages of medicines are a challenge that all health systems and countries face. Successful management of medicines shortages requires collaboration between regulators, industry, healthcare professionals and patients. This session explores how collaboration work best, and what the opportunities are to move from mitigation to prevention?
DIAmond 9 - Future of Research: Pharmaceutical Science, Innovation and Social Policy
DIAmond 10 - COVID-19, an opportunity to step up international collaboration
COVID-19 pandemic followed closely the Nitrosamines crisis (emerging in 2018), affected multiples countries and regions, and required intensive international collaboration. We look back at what went well and what can be improved.
Thursday, 18 March
DIAmond 11 - ICH E17 Guideline on Multi-Regional Clinical Trials: A Catalyst for Simultaneous Global Development and Registration
Explore the current situation with regards to implementation of ICH E17 guideline on MRCT, from regulatory authority and industry point of view. What are the key barriers to full use of the guideline internationally and how can these be addressed?
DIAmond 12 - EUnetHTA Town Hall
Friday, 19 March
DIAmond 13 - The Use of Artificial Intelligence/ Machine Learning in Pharmacovigilance
Panel Session to enable discussion of critical issues in adoption of novel technology for pharmacovigilance, including input from opinion leaders from the US and EU from both regulators and industry
DIAmond 14 - EMA 2030 and beyond - How should the EMA of the Future look like - Stakeholder Expectations
The Pharmaceutical Strategy will lead to non-legislative and legislative measures of the Pharma Acquis. To contribute to this discussion, the session is intended to collect bold visions of different stakeholders for "EMA 2030 and beyond".